Clinical trials: Epithelial Neoplasms, Malignant
Non-Small Cell Lung Cancer
Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients
The purpose of this trail is to evaluate the performance of Genetron lung cancer panel in non-small cell lung cancer patients using semiconductor sequencing method.
- Trial name
- NCT05023746
- Testing
- Genetron lung cancer panel
- Where
- 4 sites in China
- Volunteers
- 1,052 people
- Sponsor
- Genetron Health
Non-Small Cell Lung Cancer
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)
Multicenter prospective assessment of MET concordance and tumor gene profiling in treatment-naïve NSCLC
- Trial name
- Genomet (NCT07613424)
- Testing
- NGS testing, MET IHC testing, PD-L1 and Her2 testing
- Where
- 51 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
Study IPI-504-15 is a Phase 1b/2 clinical trial to evaluate the safety and efficacy of retaspimycin HCl (IPI-504) plus everolimus in patients with KRAS mutant Non-small Cell Lung Cancer (NSCLC).
- Trial name
- NCT01427946
- Testing
- IPI-504, Everolimus
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Thyroid Cancer
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
The purpose of this study is to give patients with medullary thyroid cancer either 300mg/day or 150mg/day vandetanib and compare how well each dose affects how their cancer responds.
- Trial name
- NCT01496313
- Testing
- 300mg vandetanib, 150mg vandetanib
- Where
- 30 sites in United States, Czechia and 7 more
- Volunteers
- 81 people
- Sponsor
- Sanofi
Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck
A Study of Nivolumab in Patients With Head and Neck Cancer.
A prospective real world evidence study of Nivolumab use in France in patient with recurrent or metastatic squamous cell carcinoma of the Head and Neck progressing on or after a platinum based therapy
- Trial name
- ProNiHN (NCT04050761)
- Testing
- Nivolumab
- Where
- France
- Volunteers
- 502 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer, Colorectal Tumors
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
- Conditions
- Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
- Trial name
- CheckMate 9N9 (NCT03377361)
- Testing
- Nivolumab, Trametinib, Ipilimumab
- Where
- 47 sites in United States, Argentina and 8 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Carcinoma, Non-Small-Cell Lung
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult…
- Trial name
- NCT06862869
- Testing
- Alectinib
- Where
- 44 sites in China
- Volunteers
- 800 people
- Sponsor
- Hoffmann-La Roche
Advanced Neuroendocrine Carcinoma
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
An open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)
- Trial name
- NCT06157827
- Testing
- LBL-024 for Injection, Etoposide Injection, Carboplatin Injection
- Where
- 25 sites in China
- Volunteers
- 178 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of tislelizumab administered once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in combination with chemotherapy as first-line…
- Trial name
- NCT07733180
- Testing
- Tislelizumab, Oxaliplatin, Leucovorin
- Where
- 4 sites in Japan
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Non Small Cell Lung Cancer, Pulmonary Metastases
Radiofrequency Ablation of Pulmonary Tumors Response Evaluation
The study hypothesis is that the radiofrequency (RF) ablation is a safe and effective treatment for malignant lung tumors.
- Trial name
- RAPTURE (NCT00690703)
- Testing
- RF ablation (Rita Medical Systems Model 1500x)
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 106 people
- Sponsor
- Angiodynamics, Inc.
Carcinoma, Non-Small-Cell Lung
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
The purpose of this study is to describe the clinical and health-related outcomes of amivantamab-containing regimens for the treatment of common epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC…
- Trial name
- LEPIDOPTERA (NCT07230691)
- Where
- 90 sites in Austria, Belgium and 6 more
- Volunteers
- 380 people
- Sponsor
- Janssen Research & Development, LLC
Lung Cancer, Small Cell
Regulatory Hycamtin(Oral) PMS
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of Topotecan administered in Korean patients according to the prescribing information
- Trial name
- Hycamtin PMS (NCT01037023)
- Testing
- Topotecan
- Where
- 2 sites in South Korea
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline
Gynecologic Cancer, Colorectal Cancer
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects…
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05292859
- Testing
- Neoantigen specific TCR-T cell drug product
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Oncology, Melanoma
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
- Conditions
- Oncology, Melanoma, Ovarian Cancer, NSCLC
- Trial name
- GLIMMER-01 (NCT05259696)
- Testing
- E-602, Cemiplimab
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Palleon Pharmaceuticals, Inc.
Triple Negative Breast Cancer, Hepatocellular Carcinoma
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable…
- Trial name
- NCT03318562
- Testing
- eFT508
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Effector Therapeutics
Pancreatic Neuroendocrine Tumor
Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.
The purpose of the protocol is to estimate the progression-free survival (PFS) rate in subjects diagnosed with PanNET, according to investigator assessment, at 24 months after treatment initiation with lanreotide 120 mg every 28…
- Trial name
- PanNET (NCT03947762)
- Where
- 46 sites in Portugal, Spain
- Volunteers
- 54 people
- Sponsor
- Ipsen
Small-Cell Lung Cancer, Neuroendocrine Carcinoma
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants…
- Trial name
- NCT04471727
- Testing
- Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd)
- Where
- 11 sites in United States
- Volunteers
- 232 people
- Sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Non-small Cell Lung Cancer
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
This phase II clinical study is a study to explore the efficacy and safety of BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with histologically and/or cytologically confirmed locally advanced or metastatic…
- Trial name
- NCT06498986
- Testing
- BL-B01D1, Osimertinib Mesylate Tablets
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.